Literature DB >> 18615986

Vital pulp therapy with new materials for primary teeth: new directions and Treatment perspectives.

Anna B Fuks1.   

Abstract

Vital pulp therapy aims to treat reversible pulpal injury and includes 2 therapeutic approaches: (1) indirect pulp treatment for deep dentinal cavities and (2) direct pulp capping or pulpotomy in cases of pulp exposure. Indirect pulp treatment is recommended as the most appropriate procedure for treating primary teeth with deep caries and reversible pulp inflammation, provided that this diagnosis is based on a good history, a proper clinical and radiographic examination, and that the tooth has been sealed with a leakage-free restoration. Formocresol has been a popular pulpotomy medicament in the primary dentition and is still the most universally taught pulp treatment for primary teeth. Concerns have been raised over the use of formocresol in humans, and several alternatives have been proposed. Controlled clinical studies have been critically reviewed, and mineral trioxide aggregate and ferric sulfate have been considered appropriate alternatives to formocresol for pulpotomies in primary teeth with exposed pulps. In most of the studies reviewed, the caries removal method has not been described. The use of a high-speed handpiece or laser might result in an exposure of a "normal" pulp that would otherwise not be exposed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18615986

Source DB:  PubMed          Journal:  Pediatr Dent        ISSN: 0164-1263            Impact factor:   1.874


  31 in total

1.  Evaluation of the genotoxic effects of formocresol application in vital pulp therapy of primary teeth: a clinical study and meta-analysis.

Authors:  Arnoldo Vasconcelos de Alencar Filho; Valdeci Elias Dos Santos Junior; Merilane da Silva Calixto; Neide Santos; Monica Vilela Heimer; Aronita Rosenblatt
Journal:  Clin Oral Investig       Date:  2018-02-06       Impact factor: 3.573

2.  Alternative approach for carious tissue removal in primary teeth.

Authors:  B Z Mello; T C Stafuzza; L L R Vitor; D Rios; M A Machado; T M Oliveira
Journal:  Eur Arch Paediatr Dent       Date:  2016-09-15

3.  In vitro toxicity of formocresol, ferric sulphate, and grey MTA on human periodontal ligament fibroblasts.

Authors:  S N Al-Haj Ali; S H Al-Jundi; D J Ditto
Journal:  Eur Arch Paediatr Dent       Date:  2014-10-29

4.  Long-term evaluation of primary teeth molar pulpotomies with Biodentine and MTA: a CONSORT randomized clinical trial.

Authors:  S Vilella-Pastor; S Sáez; A Veloso; F Guinot-Jimeno; M Mercadé
Journal:  Eur Arch Paediatr Dent       Date:  2021-03-08

5.  The effect of different liners on the bond strength of a compomer to primary teeth dentine: in vitro study.

Authors:  R Frankenberger; S Nassiri; S Lücker; N N Lygidakis; N Krämer
Journal:  Eur Arch Paediatr Dent       Date:  2021-02-03

6.  Relative effectiveness of direct and indirect pulp capping in the primary dentition.

Authors:  C Boutsiouki; R Frankenberger; N Krämer
Journal:  Eur Arch Paediatr Dent       Date:  2018-09-05

7.  The evaluation of MTA and Biodentine as a pulpotomy materials for carious exposures in primary teeth.

Authors:  Burcu Nihan Çelik; Merve Safa Mutluay; Volkan Arıkan; Şaziye Sarı
Journal:  Clin Oral Investig       Date:  2018-05-10       Impact factor: 3.573

8.  In vivo evaluation of the treatment outcome of pulpotomy in primary molars using diode laser, formocresol, and ferric sulphate.

Authors:  Basak Durmus; Ilknur Tanboga
Journal:  Photomed Laser Surg       Date:  2014-04-09       Impact factor: 2.796

9.  Two-year outcomes of electrosurgery and calcium-enriched mixture pulpotomy in primary teeth: a randomised clinical trial.

Authors:  F Khorakian; F Mazhari; S Asgary; M Sahebnasagh; A Alizadeh Kaseb; T Movahhed; A R Sarraf Shirazi
Journal:  Eur Arch Paediatr Dent       Date:  2014-01-17

10.  Vital pulp therapy-current progress of dental pulp regeneration and revascularization.

Authors:  Weibo Zhang; Pamela C Yelick
Journal:  Int J Dent       Date:  2010-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.